Biomarkers for understanding Ebola virus disease

Biomarkers in Medicine

Volumn 8, Issue 9, 2014, Pages 1053-1056

  McElroy, Anita K ^a,b   Spiropoulou, Christina F ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Cytokines; Ebola; EVD

Indexed keywords

ALPHA2 INTERFERON; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CD28 ANTIGEN; CD40 LIGAND; COLONY STIMULATING FACTOR 1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; D DIMER; EOTAXIN; FAS LIGAND; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEOPTERIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR I; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ADAPTIVE IMMUNITY; AFRICA SOUTH OF THE SAHARA; ANTIGEN PRESENTING CELL; APOPTOSIS; BLOOD CLOTTING DISORDER; BUNDIBUGYO VIRUS; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EDITORIAL; FLOW CYTOMETRY; HUMAN; HYPOTENSION; LIVER CELL; LYMPHOCYTOPENIA; NONHUMAN; PUBLIC HEALTH; SHOCK; SIGNAL TRANSDUCTION; SUDAN VIRUS; T LYMPHOCYTE ACTIVATION; HEMORRHAGIC FEVER, EBOLA; METABOLISM;

EBOLA VIRUS;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84911463763     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/BMM.14.75     Document Type: Editorial

References (18)

1. Sanchez A, Geisbert T, Feldmann H. Filoviridae: Marburg and Ebola Viruses (5th Edition). Wolters kluwer/Lippincott Williams & Wilkins, Philadelphia, PA, USA (2007).
2. Baize S, Pannetier D, Oestereich L et al. Emergence of Zaire Ebola virus disease in Guinea - preliminary report. N. Engl. J. Med. doi:10.1056/NEJMoa1404505 (2014) (Epub ahead of print).
3. Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev. Vaccines. 13(4), 521-531 (2014).
4. Wong G, Qiu X, Olinger GG, Kobinger GP. Postexposure therapy of filovirus infections. Trends Microbiol. doi:10.1016/j.tim.2014.04.002 (2014) (Epub ahead of print).
5. Baize S, Leroy EM, Georges AJ et al. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 128(1), 163-168 (2002).
6. Villinger F, Rollin PE, Brar SS et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J. Infect. Dis. 179(Suppl. 1), S188-S191 (1999).
7. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl. Trop. Dis. 4(10), e837 (2010).
8. Baize S, Leroy EM, Georges-Courbot MC, Capron M et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5(4), 423-426 (1999).
9. Leroy EM, Baize S, Volchkov VE et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355(9222), 2210-2215 (2000).
10. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin. Exper. Immunol. 124(3), 453-460 (2001).
11. Gupta M, MacNeil A, Reed ZD, Rollin PE, Spiropoulou CF. Serology and cytokine profiles in patients infected with the newly discovered Bundibugyo ebolavirus. Virology 423(2), 119-124 (2012).
12. Okware SI, Omaswa FG, Zaramba S et al. An outbreak of Ebola in Uganda. Trop. Med. Int. Health 7(12), 1068-1075 (2002).
13. Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J. Infect. Dis. 196(Suppl. 2), S364-S371 (2007).
14. Sanchez A, Lukwiya M, Bausch D et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J. Virol. 78(19), 10370-10377 (2004).
15. Hutchinson KL, Rollin PE. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J. Infect. Dis. 196(Suppl. 2), S357-S363 (2007).
16. McElroy AK, Erickson BR, Flietstra TD et al. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J. Infect. Dis. doi:10.1093/infdis/jiu088 (2014) (Epub ahead of print).
17. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170(6), 2797-2801 (2003).
18. Jain A, Kovacs JA, Nelson DL et al. Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand. Blood 118(14), 3811-3817 (2011).